With over 7 million people over 65 dealing with the degenerative disease — and the number expected to almost double by 2050 — Alzheimer’s is the most common form of dementia. But two new ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment "We are confident that this ...
Modified Kisunla dosing cut ARIA-E risk by 41% at 24 weeks and 35% at 52 weeks. Amyloid plaque reduction remained similar: 67% (modified) vs. 69% (original) at 24 weeks. Get a Year of Fast, Actionable ...
Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...
The European Union on Thursday approved the highly contentious Alzheimer's medication Kisunla under strict conditions, with the drug's effectiveness hotly debated by the medical community. "The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results